Peak Bio (PKBO) Stock Analysis

What Peak Bio does

Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical development phase, committed to devising treatments for critical, unmet medical needs in the realms of oncology and inflammatory disorders. The company harnesses its unique, proprietary toxin—known as PH-1 or Thailanstatin—a spliceosome modulator, to create its inaugural range of innovative Antibody-Drug Conjugate (ADC) therapies designed for cancer patients facing significant challenges. Additionally, Peak Bio's leading investigational drug, PHP-303, a small molecule, is on the verge of commencing a Phase II dose clinical trial for the rare condition Alpha1 anti-trypsin deficiency (AATD). The company's operations are situated in Palo Alto, California.

Key metrics

ETFs linked to PKBO

Broad-market and Healthcare sector ETFs an investor holding Peak Bio is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PKBO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Peak Bio?

Peak Bio trades under the ticker PKBO on NASDAQ.

Which exchange is PKBO listed on?

PKBO is listed on NASDAQ.

What sector does Peak Bio operate in?

Peak Bio is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PKBO in a portfolio?

PortView shows PKBO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.